FIP treatment and pet insurance: an unapproved antiviral, the clause that names the FDA, and an 84-day bill

GS-441524 and remdesivir at the FDA: the status on each date

Owners often hear that GS-441524 became "legal" in the US in June 2024. The FDA said the opposite in so many words. On May 10, 2024 its Center for Veterinary Medicine posted that it was aware of social media posts claiming the drug would be legally available from June 1, and reminded pharmacies, veterinarians and owners that "animal drugs compounded from bulk drug substances are unapproved drugs and are not, in fact, legal." What the agency did grant was narrower: because "no FDA approved drug is available to treat Feline Infectious Peritonitis in cats", it said it "does not intend to enforce new animal drug approval requirements" for GS-441524 compounded for a specific cat on a veterinarian's prescription, under the conditions in Guidance for Industry #256.

That is enforcement discretion, not approval, and for insurance the distinction is the whole story. The table sets out each status with the FDA page that supports it and the date that page carries.

Statuses change. Before relying on any row, look for a newer notice on the FDA Center for Veterinary Medicine updates page. Nothing in the table is advice on which drug a cat should receive.

Two rows carry most of the weight. The first is the bulk-compounding row. The FDA's own question-and-answer page on GFI #256, current as of August 27, 2026, puts the point bluntly: "An animal drug compounded from a bulk drug substance is not equivalent to an FDA-approved drug, even if they contain the same active ingredient." No amount of quality testing by a pharmacy changes that label. A policy that pays only FDA-approved medication is reading a status the FDA itself says compounded GS-441524 does not have.

The second is the remdesivir row, which cuts the other way. Remdesivir is an FDA-approved drug, just not for cats. Merck explains that GS-441524 is the active metabolite of remdesivir and that both have been found effective for FIP, and it describes some protocols that start with injectable remdesivir before moving to oral GS-441524. A drug approved for people and used outside its label sits in a different box from a drug that was never approved at all, and some policy wording draws exactly that line while other wording never mentions it. The draft GFI #256B row changes nothing yet; until it is finalized it is a proposal, and it concerns where compounding may happen rather than whether the product is approved.

FDA-approved, compounded, experimental: the drug wording in six documents

An FIP claim passes through two filters before any deductible arithmetic starts. One is the medication definition: does the policy pay for this kind of drug? The other is the experimental or standard-of-care exclusion: does the policy refuse treatment that is new or not generally accepted? Each document below was read in full on October 30, 2026, and every phrase in quotation marks is the document's own. The sample policies are single-state or single-species examples; a cat's own declarations page and policy form are what govern.

None of the five policy documents names FIP, GS-441524 or remdesivir. The Lemonade entry is a published statement on the insurer's site, not a contract term; the policy form governs.

The documents fall into three groups, and the grouping is the most useful thing an FIP owner can take from them. Spot, Figo and Embrace tie the medication benefit to FDA approval (or, for Figo and Embrace, inclusion in the Homeopathic Pharmacopoeia). MetLife and AKC define medication by who prescribes and dispenses it, with no approval test at all, and MetLife names compounding outright. Lemonade has said in public that FIP treatment is often covered, without quoting a drug definition alongside.

Figo's mention of compounding is easy to misread. The phrase "compounded by a pharmacist" sits inside a sentence about FDA-approved or Homeopathic Pharmacopoeia drugs sold over the counter: it describes how such a drug must reach the cat, not a separate category of covered compounded drugs. A bulk-compounded antiviral is not an FDA-approved drug to begin with, so that sentence does not reach it on its plain words.

The experimental clauses are worded differently enough to matter. Spot's exclusion is qualified: it bites on treatment "not generally accepted in the veterinary medical community as effective or proven." Against that test, an insurer and an owner could both point to Merck, which calls oral GS-441524 a treatment most cats with FIP can be successfully treated with, and to Cornell, which says studies suggest it is "a safe and effective treatment option". Figo's and AKC's exclusions carry no such qualifier; they simply exclude experimental treatment, without saying who decides what is experimental. Neither reference uses the word for GS-441524, but neither policy defines it either.

Why "approved by the FDA" is the phrase to settle first

On a policy whose medication benefit names the FDA, the most direct reading is short. The FDA says bulk-compounded drugs are unapproved and "not equivalent to an FDA-approved drug". Enforcement discretion is a decision not to act, and the May 2024 notice is careful never to call it anything else. If the benefit requires approval, compounded GS-441524 does not meet the requirement on the words alone, however well made the tablet is.

That reading still leaves real gaps, and they are worth raising with an insurer before a claim rather than after. Spot's wording says "approved by the Food and Drug Administration" without saying approved for which species or which disease, so a human-approved drug used extralabel, such as injectable remdesivir, is a closer case than compounded GS-441524. A remdesivir product compounded from an approved finished drug rather than from bulk is closer still, since the FDA treats compounding from approved drugs as generally permissible under certain conditions, though the result is itself not an approved product. And an insurer may choose to pay more than its form requires; Lemonade's public statement is an example of a company describing FIP cover in broad terms. None of the documents says how its company has actually decided an FIP antiviral claim, and nothing here predicts one.

This is not the first time the approval word has decided a claim line on this site. The epilepsy guide follows the same clause through potassium bromide and phenobarbital, where the open issue is conditional approval and human-market tablets. The hyperthyroid cat guide meets it with compounded transdermal methimazole. FIP is the starkest case of the three, because there is no approved product to fall back on: the choice is between an unapproved compounded drug and no antiviral at all.

Six lines an FIP invoice might carry, and the wording each one meets

An FIP claim is rarely one charge. The rows below separate the lines a treated cat's file commonly contains, using the drugs Merck and Stokes Pharmacy name and the supportive care Cornell lists, and apply the wording from the table above. These are readings of quoted text against stated facts, not predictions of a decision, and they say nothing about which treatment a cat should have.

Rows 5 and 6 matter more than they look. When an FDA-approval clause takes the antiviral off the claim, the tests, exams and supportive care can still be covered illness costs, and over a three-month course they add up. An owner who hears "the drug isn't covered" should ask in the same breath whether the rest of the FIP claim is.

Kittens, short waiting periods and the first fever in the chart

FIP is a young cat's disease more often than not, and that collides with the way policies date a condition. Cornell says approximately 70 percent of cases are diagnosed in cats less than 1 1/2 years old and 50 percent in cats less than 7 months old. It adds that the feline enteric coronavirus is most often passed from mother to kittens when they are between five and eight weeks of age, and that FIP can develop weeks, months or even years after exposure. Many FIP claims will therefore come from cats enrolled only weeks or months before.

Waiting periods for illness are short on the forms read, but they are not zero. Spot's Arizona sample has a 14 day waiting period for illness, Figo's sample sets fourteen days for illnesses, and AKC's North Carolina sample sets five days before it will cover an illness. MetLife's sample puts the waiting period on the declarations page rather than in the form. Lemonade says it can cover a cat from two months old. A kitten adopted at eight to ten weeks and insured the same week is inside a waiting period for the first few days or weeks of exactly the age band Cornell describes.

The bigger risk is a note made before cover started. Merck lists nonspecific signs that are common in FIP: lethargy, poor appetite, weight loss or failure to gain weight, and a fluctuating fever that does not respond to antimicrobials. Each of those can appear in a shelter or first-visit record long before anyone says the letters FIP. The pre-existing definitions are written to catch them. Spot's form treats as pre-existing any condition that "first occurs or shows symptoms before coverage is effective or during a waiting period." MetLife's turns on whether, before continuous coverage began, a veterinarian gave advice, the pet received a diagnosis, care or treatment, or "the Pet displayed signs or symptoms consistent with the Illness or Injury." A fever charted at the adoption exam and an FIP diagnosis two months later can be linked under either wording, even though nobody suspected FIP at the time.

Cornell Feline Health Center, Feline Infectious Peritonitis (updated 2024); Merck Veterinary Manual, Feline Infectious Peritonitis (updated April 2026). Neither reference ranks breeds by risk, and these are population figures that say nothing about an individual cat.

For a kitten from a shelter or a cattery, the practical step is paperwork rather than prediction. Ask the shelter or breeder for every record, including weights and temperatures, and read them before enrolling, because the insurer will read them after the first claim. A shelter kitten's intake record can also carry an FIV antibody result, and the FIV-positive cat guide shows how seven policy documents date that line against the policy start. The waiting periods guide explains how each clock starts, and the pre-existing conditions guide shows how a single chart note is matched to a later diagnosis.

After the last tablet: remission, relapse, renewals and switching insurers

Merck says treatment "should not be stopped early, even if clinical improvement is rapid", and Stokes notes that if a cat is not responding as expected the amount of antiviral may need to be increased. For insurance, that means a course can run longer or cost more than the first estimate, and a retreatment, if a veterinarian recommends one, is billed as further treatment of the same condition. How a second round is counted depends on the form's incident and limit structure.

AKC's sample is the clearest example of why structure matters. It defines an Incident as "a specifically identifiable Illness or Injury" and adds: "If an Incident is recurring or chronic, it will be considered one (1) Incident." On a plan with a per-incident limit, a first course and a retreatment for the same FIP draw down one limit. On a plan with an annual limit, the limit refills at renewal. On a plan with no limit, neither applies. None of that is visible on a premium quote; it is on the declarations page.

Switching insurers after a cat recovers is the other trap. To any new insurer, FIP is a condition the cat has already had. Spot's sample offers a narrow route back: if a pre-existing condition "is curable and has been cured and free from treatment and symptoms for a period of 180 days it is a new occurrence", but the same sentence says this does not apply to chronic conditions. Whether a recovered FIP cat counts as cured is a question the form does not answer, and a later illness that a new insurer links to FIP could be refused as pre-existing. Keeping the policy that paid the first claim, and renewing it without a lapse, avoids that question entirely. The switching guide covers the gap risk in more detail.

Paying the pharmacy first and claiming afterward

Most FIP antiviral orders are paid by the owner up front. Stokes says on its cat-owner page that it is "not contracted with any pet insurance companies" and suggests contacting the insurance provider about reimbursement. The same page points owners to a May 2024 Trupanion announcement about FIP medication; any owner relying on that company's position should ask it for its current answer in writing, because a two-year-old announcement is not a policy term.

A reimbursement claim for a pharmacy order needs the same proof as any other. MetLife's sample asks for itemized invoices and medical records from the veterinary provider and, on a first claim, the pet's medical and adoption records for the twelve months before the date of service, and it wants the claim within 90 days of that date. Figo's sample says items bought from an outside store or other pharmacy are not covered unless prescribed by a veterinarian. For a three-month course bought in several orders, that means keeping each pharmacy invoice with a copy of the prescription it filled, and claiming each order inside the deadline rather than waiting until the course ends.

If the claim is refused or only partly paid, the bill does not shrink. The guide to help paying vet bills sets out charity and clinic options, and the vet financing guide compares credit lines and payment plans, both of which some owners use to bridge the weeks between paying a pharmacy and receiving a reimbursement.